Stoke Therapeutics, Inc. (STOK)

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Antisense Oligonucleotide	8.78M
Antisense Oligonucleotide Growth	-29.22%

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
United States	8.78M
United States Growth	-29.22%